Percentage shown represents frequency of patients receiving of stated treatment modality.

RT indicates radiotherapy; CMT, combined modality therapy; CHT, chemotherapy alone; and NR, not reported.

Study included all stages (81% early stage). Presented here is only information for stage 1 and 2 patients; CHT indicates the following: MOPP-like, 49%; ABVD-like, 4%; MOPP/ABVD-like, 36%; and other, 11%.

GHSG trial patients included all stages (79% early stage). Reported here are results for early stage. Early unfavorable defined as stage I or II with GHSG risk factors, bulky mediastinal mass, extranodal lesions, massive spleen involvement, increased erythrocyte sedimentation rate (≥ 50 mm without B symptoms or ≥ 30 with B symptoms), ≥ 3 nodal areas. Early stage favorable CHT used, COPP/ABVD or ABVD; and early stage unfavorable CHT used, COPP/ABVD, ABVD, or BEACOPP.

Population-based study: 3% B symptoms and 1% bulky disease.

Population-based study: calculated 10-year recurrence rate accounting for deaths from nonlymphomatous causes.

Current series population-based study; excludes 2 patients treated with surgery alone.

GOEL-AMS trial patients: CHT 1 to 3 cycles of ABVD or EBVM.

Population-based study included all stages (78% early stage). Presented here are results for early stage. One patient with stage 1A disease treated with surgery alone. CHT variable, LOPP (chlorambucil, vincristine, procarbazine, and prednisone), ChlVPP (chlorambucil, vinblastine, procarbazine, and prednisolone), MOPP, VEEP (vincristine, epirubicin, etoposide, and prednisolone), VAPEC-B (doxorubicin, cyclophosphamide, etoposide, vincristine, bleomycin, and prednisolone), and ABVD.

Prospective studies at MDACC. Outcomes only reported by treatment received: CHT indicates MOPP or NOVP (mitoxantrone, vincristine, vinblastine, and prednisone). Difference was not statistically significant.